内皮eNAMPT放大临床前急性肺损伤:eNAMPT中和单克隆抗体的疗效
本研究在LPS单次打击和LPS联合机械通气两次打击的临床前急性肺损伤模型中,验证了内皮来源的细胞外烟酰胺磷酸核糖转移酶(eNAMPT)在肺损伤中的作用,并评估了eNAMPT中和抗体(多克隆和单克隆ALT-100)的疗效。结果显示,eNAMPT表达随时间增加,静脉给予中和抗体可显著减轻炎症性肺损伤,体外实验证实抗体可阻断eNAMPT诱导的TLR4通路激活和内皮屏障破坏。
要点
- eNAMPT在临床前ARDS模型中表达随时间增加,内皮来源eNAMPT显著加重肺损伤。
- eNAMPT中和抗体(pAb或ALT-100 mAb)静脉给药可减轻炎症性肺损伤。
- 抗体可阻断eNAMPT诱导的TLR4通路激活和内皮屏障破坏。
核心结论
- 内皮来源的eNAMPT参与临床前急性肺损伤的严重程度,靶向eNAMPT/TLR4通路具有治疗潜力。
研究设计与样本
- 野生型C57BL/6J或内皮细胞cNAMPT-/-敲除小鼠暴露于LPS单次打击或LPS联合机械通气两次打击诱导的急性炎症性肺损伤模型。
主要发现
- 免疫组化、生化和影像学研究证实两种临床前ARDS模型中NAMPT肺组织表达随时间增加。
- 静脉给予eNAMPT中和多克隆抗体或单克隆抗体显著减轻两种模型中的炎症性肺损伤(HE染色、BAL蛋白、BAL多形核细胞、血浆IL-6)。
- 体外人类肺内皮细胞研究显示eNAMPT中和抗体强烈减弱eNAMPT诱导的TLR4通路激活和内皮屏障破坏。
- 野生型和EC-cNAMPT-/-小鼠体内研究证实内皮来源NAMPT对两种模型炎症性肺损伤严重程度有高度显著贡献。
临床怎么用
- eNAMPT/TLR4通路可能成为ARDS治疗靶点,联合eNAMPT生物标志物和NAMPT基因分型可识别高风险ARDS患者进行个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: The severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 pandemic has highlighted the serious unmet need for effective therapies that reduce acute respiratory distress syndrome (ARDS) mortality. We explored whether extracellular nicotinamide phosphoribosyltransferase (eNAMPT), a ligand for Toll-like receptor (TLR)4 and a master regulator of innate immunity and inflammation, is a potential ARDS therapeutic target. METHODS: Wild-type C57BL/6J or endothelial cell (EC)-cNAMPT -/- knockout mice (targeted EC NAMPT deletion) were exposed to either a lipopolysaccharide (LPS)-induced ("one-hit") or a combined LPS/ventilator ("two-hit")-induced acute inflammatory lung injury model. A NAMPT-specific monoclonal antibody (mAb) imaging probe (99mTc-ProNamptor) was used to detect NAMPT expression in lung tissues. Either an eNAMPT-neutralising goat polyclonal antibody (pAb) or a humanised monoclonal antibody (ALT-100 mAb) were used in vitro and in vivo. RESULTS: Immunohistochemical, biochemical and imaging studies validated time-dependent increases in NAMPT lung tissue expression in both pre-clinical ARDS models. Intravenous delivery of either eNAMPT-neutralising pAb or mAb significantly attenuated inflammatory lung injury (haematoxylin and eosin staining, bronchoalveolar lavage (BAL) protein, BAL polymorphonuclear cells, plasma interleukin-6) in both pre-clinical models. In vitro human lung EC studies demonstrated eNAMPT-neutralising antibodies (pAb, mAb) to strongly abrogate eNAMPT-induced TLR4 pathway activation and EC barrier disruption. In vivo studies in wild-type and EC-cNAMPT -/- mice confirmed a highly significant contribution of EC-derived NAMPT to the severity of inflammatory lung injury in both pre-clinical ARDS models. CONCLUSIONS: These findings highlight both the role of EC-derived eNAMPT and the potential for biologic targeting of the eNAMPT/TLR4 inflammatory pathway. In combination with predictive eNAMPT biomarker and NAMPT genotyping assays, this offers the opportunity to identify high-risk ARDS subjects for delivery of personalised medicine.
引用
- Quijada H, Bermudez T, Kempf CL, et al. Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody. Eur Respir J. 2021. PMID: 33243842. doi:10.1183/13993003.02536-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。